Catalogue: Resources for COVID-19 and influenza vaccine development
Posted: 18 June 2021 | Sino Biological Inc. | No comments yet
A panel of SARS-CoV-2 reagents (e.g. antigens, antibodies, and kits) and influenza antigens have been developed to support the development of vaccines.
To support the development of COVID-19 and influenza vaccine, Sino Biological has developed a large collection of SARS-CoV-2 reagents, including recombinant antigens, recombinant mutants, neutralising antibodies, and specific antibodies as well as 630+ HA, NA, and ME antigens from over 250 strains of influenza viruses, including vaccine strains and the pandemic strains.
Related content from this organisation
Related topics
Antibodies, Assays, Biomarkers, Biopharmaceuticals, Disease research, Immunology, Targets
Related organisations
Sino Biological Inc.